Life sciences · Journal article

Beta-Blockers Versus Flecainide for Atrial Fibrillation: A First-Line Strategy Review of Efficacy, Safety, and Patient Selection

Cardiology in Review · July 6, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This evidence-based review synthesizes landmark AF trials and current guidelines to guide first-line pharmacotherapy selection between beta-blockers and flecainide. The primary determinant is presence or absence of structural heart disease: beta-blockers are mortality-reducing and safe in structural disease; flecainide offers superior rhythm control in structurally normal hearts but is contraindicated in structural disease due to proarrhythmic risk. No direct head-to-head trial of these agents as monotherapy exists.

What was studied

Journal article. Patients with atrial fibrillation requiring first-line pharmacotherapy, stratified by presence or absence of structural heart disease (coronary artery disease, heart failure with reduced ejection fraction, left ventricular hypertrophy)..

Key findings

Beta-blockers are safe and mortality-reducing in patients with structural heart disease (coronary artery disease, heart failure with reduced ejection fraction, left ventricular hypertrophy) and effective for both rate and rhythm control Flecainide offers superior rhythm control efficacy but is absolutely contraindicated in structural heart disease due to proarrhythmic risk, as demonstrated by the Cardiac Arrhythmia Suppression Trial In patients with structurally normal hearts, flecainide is a first-line rhythm-control option, including pill-in-the-pocket strategy

Safety

Who this may help

Clinicians should use structural heart disease status as the primary determinant of first-line agent selection: beta-blockers for patients with structural disease (mortality benefit), flecainide for structurally normal hearts seeking rhythm control. The absence of direct head-to-head comparison means this guidance relies on mechanistic differences and indirect evidence.

Plain-language summary

A state-of-the-art clinical review synthesizing landmark trials and recent guidelines to provide evidence-based recommendations for first-line AF drug selection, without new primary data.

Reported figures

Quoted from the source exactly as published.

Primary decision criterionPresence or absence of structural heart disease

Clinical bottom line

Caveats

No direct head-to-head RCT of beta-blockers versus flecainide as monotherapy is reported
Role of these agents in the era of early ablation and in heart failure with preserved ejection fraction described as ongoing uncertainties, not resolved
Specific efficacy rates, absolute risk reductions, and confidence intervals for individual agents are not quantified in this review text
Guidelines cited (ACC/AHA/ACCP/HRS 2023, ESC 2020) are referenced but full guideline statements are not extracted

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Systematic synthesis of landmark RCTs and current guidelines; no primary data collection.

Directness

strong

Directly addresses first-line AF pharmacotherapy choice in clinical practice.

Consistency

strong

Cites concordant evidence from CAST, AFFIRM, RACE, EAST-AFNET 4 and ACC/AHA/ACCP/HRS and ESC guidelines.

Risk of bias

moderate

Review synthesizes existing trials; no direct head-to-head comparison of agents reported.

Sample adequacy

moderate

Based on landmark trials; scale not quantified for this synthesis.

Source abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The choice of initial pharmacotherapy-rate control versus rhythm control and which agent-is a critical clinical decision. Beta‑blockers and flecainide are both used first line, but have distinct mechanisms and safety profiles that dictate appropriate patient selection. This state‑of‑the‑art review provides a clinically focused, evidence‑based comparison of beta‑blockers and flecainide for first‑line AF management, emphasizing patient selection and practical decision‑making, synthesizing data from landmark trials (Cardiac Arrhythmia Suppression Trial, Atrial Fibrillation Follow-up Investigation of Rhythm Management, RACE, EAST‑AFNET 4), recent guidelines (American College of Cardiology/American Heart Association/American College of Chest Physicians/Heart Rhythm Society 2023, European Society of Cardiology 2020), and contemporary studies. Beta‑blockers are safe and mortality‑reducing in patients with structural heart disease (coronary artery disease, heart failure with reduced ejection fraction, left ventricular hypertrophy) and are effective for both rate and rhythm control. Flecainide offers superior rhythm control efficacy but is absolutely contraindicated in structural heart disease due to proarrhythmic risk (Cardiac Arrhythmia Suppression Trial). In patients with structurally normal hearts, flecainide is a first‑line rhythm‑control option, including a "pill‑in‑the‑pocket" strategy. No direct head‑to‑head trial compares beta‑blockers versus flecainide as monotherapy. The presence or absence of structural heart disease is the primary determinant of first‑line drug selection. A practical clinical algorithm based on this assessment is provided to guide therapy. Ongoing uncertainties include the role of these agents in the era of early ablation and in heart failure with preserved ejection fraction.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

May Thu Kyaw